Literature DB >> 16965434

Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain.

I García-Doval1, E Mayo, J Nogueira Fariña, M J Cruces.   

Abstract

BACKGROUND: Influenza vaccination has been suggested to be a trigger for bullous pemphigoid (BP). In our area most new patients with BP are admitted to hospital.
OBJECTIVES: To detect a difference in the rate of admissions to hospital for BP during population influenza vaccination programmes, which are mainly targeted at individuals aged 65 years or older, start in the last week of September and last for 2 months.
METHODS: An ecological study in Galicia, north-west Spain (1997-2005), restricted to people aged 65 years or older. Using Poisson regression, results were controlled for mean age of admission and percentage of the population vaccinated each year.
RESULTS: There were 29 admissions registered during 'vaccination periods' (i.e. approximately 10 weeks per year, including the period of vaccination and two further weeks), and 158 during nonvaccination periods (the rest of the year). The incidence rate ratio of admissions for BP in vaccination vs. nonvaccination periods was 0.85 (95% confidence interval 0.57-1.27, P = 0.43).
CONCLUSIONS: Our data do not support the hypothesis of influenza vaccination being an important trigger for severe BP on a population level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965434     DOI: 10.1111/j.1365-2133.2006.07411.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Bullous eruption in a five-month-old girl.

Authors:  Aida Khaled; Monia Kharfi; Becima Fazaa; Mohamed Ridha Kamoun
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

2.  Bullous pemphigoid and COVID-19 vaccine.

Authors:  Israel Pérez-López; David Moyano-Bueno; Ricardo Ruiz-Villaverde
Journal:  Med Clin (Barc)       Date:  2021-05-27       Impact factor: 1.725

3.  Case of bullous pemphigoid following coronavirus disease 2019 vaccination.

Authors:  Kenta Nakamura; Megumi Kosano; Yuzuki Sakai; Nana Saito; Yuko Takazawa; Toshikazu Omodaka; Yukiko Kiniwa; Ryuhei Okuyama
Journal:  J Dermatol       Date:  2021-09-21       Impact factor: 4.005

4.  Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study.

Authors:  Carlo Alberto Maronese; Marzia Caproni; Chiara Moltrasio; Giovanni Genovese; Pamela Vezzoli; Paolo Sena; Giulia Previtali; Emanuele Cozzani; Giulia Gasparini; Aurora Parodi; Laura Atzori; Emiliano Antiga; Roberto Maglie; Francesco Moro; Elena Biancamaria Mariotti; Alberto Corrà; Sabatino Pallotta; Biagio Didona; Angelo Valerio Marzano; Giovanni Di Zenzo
Journal:  Front Med (Lausanne)       Date:  2022-02-28

5.  Bullous pemphigoid following COVID-19 vaccine: An autoimmune disorder.

Authors:  Aneesh Rai; Govinda Khatri; Mohammad Mehedi Hasan
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31

6.  Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.

Authors:  S M Langan; L Smeeth; R Hubbard; K M Fleming; C J P Smith; J West
Journal:  BMJ       Date:  2008-07-09

Review 7.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.